Virginia Mason was today named a recipient of Healthgrades Outstanding Patient Experience Award for the second consecutive year. This distinction places it among the top 10 percent of hospitals in the nation for patient experience.
Each year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer.
PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.
A new study by researchers at Rush University Medical Center reviews research that suggests that the risk for developing Alzheimer's disease among older African Americans may be two to three times greater than in the non-Hispanic white population and that they differ from the non-Hispanic white population in risk factors and disease manifestation.
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
Seniors living in the community who have dementia are more likely to be hospitalized and visit the emergency department than those who do not have dementia, according to a new study by researchers at RTI International.
Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat Tse, Professor of Cardiovascular Medicine, The University of Hong Kong and Department of Medicine, Queen Mary Hospital in Pokfulam, Hong Kong, under the proctorship of Dr. Martin Stiles, Director of Electrophysiology, Waikato Hospital in Hamilton, New Zealand.
Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.
UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.
South Korean researchers have reported a rare case of tuberculous otitis media and say that ear tuberculosis should be considered in patients presenting with otitis media complicated by facial paralysis.
Initial blood pressure measurements in patients with diabetes should be taken from both arms, say researchers.
The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.
Algatechnologies Ltd., a leading manufacturer and supplier of natural algae astaxanthin announces the launch of AstaPure 20% astaxanthin oleoresin. This content of astaxanthin exceeds any available in the marketplace.
Chromogenex, a world leader in laser innovation, announced today the launch of i-LipoXcell, the company's non-surgical fat reduction and body shaping system. Representing third generation technology, i-LipoXcell incorporates both visible red and infrared lasers for bio-stimulation of metabolic pathways, effectively shrinking fat cells through the release of fatty acids and glycerol.
Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.
Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects.
Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Meda has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates have been established.